Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265268 | 1.00 | RORC (0.47) | RORCMAPTTHRBFAAHTP53 | |
| SCHEMBL7018874 | 1.00 | RORC (0.47) | RORCMAPTTHRBFAAHTP53 | |
| SCHEMBL5226630 | 0.90 | RORC (0.52) | RORCMAPTTHRBTP53LMNA | |
| SCHEMBL264850 | 0.90 | RORC (0.52) | RORCMAPTTHRBTP53LMNA | |
| SCHEMBL2789725 | 0.90 | RORC (0.52) | RORCMAPTTHRBTP53LMNA | |
| Hydrochloric Acid SCHEMBL5258121 | 0.89 | RORC (0.51) | RORCMAPTTHRBTP53LMNA | |
| Hydrochloric Acid SCHEMBL3457382 | 0.89 | RORC (0.51) | RORCMAPTTHRBTP53LMNA | |
| SCHEMBL22570215 | 0.74 | RORC (0.48) | RORCTP53LMNAMDM2HPGD | |
| SCHEMBL28079605 | 0.74 | RORC (0.48) | RORCTP53LMNAMDM2HPGD | |
| SCHEMBL5132529 | 0.73 | MEN1 (0.46) | MAPTTHRBALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272966-B2 | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane | KOWA COMPANY, LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-9272966-B2 | Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane | KOWA COMPANY, LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | KOWA COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | KOWA COMPANY, LTD. (JP) | 2013-07-25 | — | — | US | disclosed |
| US-8133994-B2 | Preparation of aprepitant | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-03-13 | — | — | US | disclosed |
| US-20110094321-A1 | PREPARATION OF APREPITANT | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-04-28 | — | — | US | disclosed |
| EP-1942734-A2 | PREPARATION OF APREPITANT | Dr. Reddy's Laboratories Ltd. (IN) | 2008-07-16 | — | — | EP | disclosed |
| EP-1462450-B1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME (GB) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007044829-A2 | PREPARATION OF APREPITANT | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-04-19 | — | — | WO | disclosed |
| EP-1099702-B1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME (GB) | 2004-10-06 | — | — | EP | disclosed |
| WO-1996029328-A1 | MORPHOLINE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-09-26 | — | — | WO | disclosed |
| WO-1996020197-A1 | SPIROKETAL DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
| US-5512570-A | Treatment of emesis with morpholine tachykinin receptor antagonists | MERCK & CO., INC. (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1996005181-A1 | MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
| US-5457107-A | For treating inflammatory diseases, pain or migraine, asthma and emesis | MERCK & CO., INC. (US) | 1995-10-10 | — | — | US | disclosed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995018124-A1 | SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-07-06 | — | — | WO | disclosed |
| WO-1995016679-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
| WO-1994000440-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0577394-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190540-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE 1-BROMO-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHANE | RPP30, BRPF1, ALK | RORC 3213/4885MAPT 4581/4885THRB 1549/4885 |
| US-20110094321-A1 | PREPARATION OF APREPITANT | KIT, CPA3, CMA1 | RORC 1521/4885MAPT 4001/4885THRB 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.